<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376972</url>
  </required_header>
  <id_info>
    <org_study_id>RFX-VAG/003/2012</org_study_id>
    <nct_id>NCT02376972</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis</brief_title>
  <acronym>VARIANT</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alfasigma S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF&#xD;
      RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      THIS IS A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626&#xD;
      SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS.&#xD;
&#xD;
      PRIMARY ENDPOINT:&#xD;
&#xD;
      TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS&#xD;
      PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS&#xD;
&#xD;
      SECONDARY ENDPOINT:&#xD;
&#xD;
      TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS&#xD;
      METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    According to the Recommendation of the Indipendent Data Monitoring Committee&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CLINICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 22-30</time_frame>
    <description>RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA, I.E. NORMAL PHYSIOLOGICAL DISCHARGE, NEGATIVE &quot;WHIFF TEST&quot;, CLUE CELLS &gt;20%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 22-30</time_frame>
    <description>GRAM STAIN NUGENT SCORE &lt;4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THERAPEUTIC CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 22-30</time_frame>
    <description>AMSEL'S CRITERIA AND GRAM STAIN NUGENT (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE &lt;4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF CLINICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 61-70</time_frame>
    <description>AMSEL'S CRITERIA (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 61-70</time_frame>
    <description>NUGENT SCORE &lt;4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF THERAPEUTIC CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>60-69 DAYS AFTER THE FIRST DAY OF TREATMENT</time_frame>
    <description>AMSEL'S CRITERIA AND NUGENT SCORE (MAINTENANCE OF RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE &lt;4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NUMBER, INTENSITY AND TYPE OF ADVERSE EVENTS</measure>
    <time_frame>Up to Day 70</time_frame>
    <description>The incidence of adverse events to be summarized by body system and MedDRA preferred term.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LOCAL OBJECTIVE TOLERABILITY</measure>
    <time_frame>Day 22-30</time_frame>
    <description>Vaginal mucosa status in terms of erythema (score 0 to 3), edema (score 0 to 3), pethechial hemorrhages (absence/presence), ulcers (absence/presence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LOCAL SUBJECTIVE TOLERABILITY</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>Grade (from 0 to 4) of vaginal itching, pain and burning</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>BACTERIAL VAGINOSIS</condition>
  <arm_group>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 25 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 100 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO VAGINAL TABLET</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>METROGEL VAGINAL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIFAXIMIN VAGINAL TABLET 25 MG</intervention_name>
    <description>RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 25 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIFAXIMIN VAGINAL TABLET 100 MG</intervention_name>
    <description>RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 100 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO VAGINAL TABLET</intervention_name>
    <description>PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>PLACEBO VAGINAL TABLET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>METROGEL VAGINAL</intervention_name>
    <description>METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>METROGEL VAGINAL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of bacterial vaginosis with Amsel's criteria (4 out of 4 fulfilled&#xD;
             criteria):&#xD;
&#xD;
               -  Off white (milky or gray), thin, homogeneous, adherent vaginal discharge&#xD;
&#xD;
               -  pH &gt;4.5&#xD;
&#xD;
               -  Positive &quot;whiff test&quot;&#xD;
&#xD;
               -  Presence of clue cells ≥20%&#xD;
&#xD;
          -  Bacteriological diagnosis of bacterial vaginosis with Gram stain Nugent score ≥ 4&#xD;
             (patients may be enrolled/randomized without this result)&#xD;
&#xD;
          -  Post-menarchal, pre-menopausal female patient&#xD;
&#xD;
          -  Non-pregnant (negative urine pregnancy test at Entry Visit/V1) nor breast-feeding&#xD;
             patient&#xD;
&#xD;
          -  Patient aged between 18 50 years, inclusively&#xD;
&#xD;
          -  Patient who is willing to be asked questions about personal medical health and sexual&#xD;
             history&#xD;
&#xD;
          -  Patient capable of and willing to conform to the study protocol&#xD;
&#xD;
          -  Patient who have been thoroughly informed of the aim of the study and the study&#xD;
             procedures and who provided signed and dated written informed consent form&#xD;
&#xD;
          -  Patient who agrees to abstain from intercourse during the 5 day treatment period&#xD;
&#xD;
          -  Patient who agrees also to abstain from intercourse 3 days before the scheduled visits&#xD;
             of follow-up&#xD;
&#xD;
          -  Patient who agrees to abstain from the use of any other intravaginal product (i.e.,&#xD;
             douching, feminine deodorants sprays, tampons, spermicides, gels, foams, vaginal birth&#xD;
             control ring and diaphragms) during the entire study period&#xD;
&#xD;
          -  Patient who agrees to use an adequate method of birth control for the duration of the&#xD;
             study to avoid pregnancy. Acceptable methods include a history of bilateral tubal&#xD;
             ligation, male partner with a vasectomy, a hormonal contraceptive [oral, patch,&#xD;
             injectable or implantable (excluding intrauterine implantable devices [IUD],&#xD;
             intrauterine system [IUS] and vaginal rings), or abstinence&#xD;
&#xD;
          -  Patient who agrees to abstain from alcohol ingestion during the 5-day treatment period&#xD;
             and for 1 day afterward&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Virginity&#xD;
&#xD;
          -  Patient with other infectious causes of vulvovaginitis (e.g., candidiasis, Trichomonas&#xD;
             vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, active Herpes simplex&#xD;
             lesions, or Human Papilloma Virus lesions); patients may be enrolled/randomized&#xD;
             without these results)&#xD;
&#xD;
          -  Other vulvovaginal or cervical conditions, abnormalities or disorders confounding the&#xD;
             interpretation of clinical response (including total hysterectomy)&#xD;
&#xD;
          -  Symptoms suggestive of pelvic inflammatory disease&#xD;
&#xD;
          -  Patient with intra uterine device (IUD), intrauterine system (IUS), or vaginal ring as&#xD;
             contraceptive method&#xD;
&#xD;
          -  Patient with severe hepatic insufficiency (Child C)&#xD;
&#xD;
          -  Patient with severe cardiac insufficiency (NYHA - New York Heart Association classes 3&#xD;
             - 4)&#xD;
&#xD;
          -  Patient who will be being evaluated, including colposcopy and cervical biopsies, or&#xD;
             being treated during the study period, for abnormal Pap test or cervical carcinoma. To&#xD;
             note that if the Pap test will be performed at baseline, the result will be known&#xD;
             after the randomization visit: patients may be enrolled without this result&#xD;
&#xD;
          -  Any condition or circumstance that would prevent completion of the study or interfere&#xD;
             with analysis of study results, including a history of drug or alcohol abuse, mental&#xD;
             illness or non-compliance with treatments or visits, immunological (including HIV&#xD;
             infection), hematological or neoplastic disease (including all cervical neoplastic&#xD;
             diseases)&#xD;
&#xD;
          -  Cervical cryotherapy, loop electrosurgical excision (LEEP), cervical laser, or any&#xD;
             other ablative or excisional cervical procedures within the last 3 months&#xD;
&#xD;
          -  Vaginal laser within the last 3 months&#xD;
&#xD;
          -  Patient with clinically relevant pathological laboratory values&#xD;
&#xD;
          -  Known hypersensitivity to rifaximin&#xD;
&#xD;
          -  Known hypersensitivity to excipients present in rifaximin, placebo or metronidazole&#xD;
             formulations&#xD;
&#xD;
          -  Known hypersensitivity to metronidazole, either orally or topically administered, or&#xD;
             any forms of parabens&#xD;
&#xD;
          -  Concurrent anticoagulant therapy with coumadin or warfarin&#xD;
&#xD;
          -  Menstruating or anticipated menstruation/withdrawal bleed at Entry Visit/V1 and during&#xD;
             the drug administration&#xD;
&#xD;
          -  Patient who received antifungal or antimicrobial therapy (systemic or intravaginal)&#xD;
             within 14 days of randomization&#xD;
&#xD;
          -  Patient who have participated in another clinical trial or have taken an&#xD;
             investigational drug within the last 4 weeks prior screening&#xD;
&#xD;
          -  Patient who has taken disulfuram within the last 14 days&#xD;
&#xD;
          -  Withdrawal of informed consent&#xD;
&#xD;
          -  Patient previously randomized in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffaella Tacchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alfasigma S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Medicine Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>191012-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

